Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Posts Earnings Results, Misses Estimates By $2.78 EPS

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) released its earnings results on Wednesday. The company reported ($3.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($2.78), FiscalAI reports. The firm had revenue of $0.79 million during the quarter, compared to the consensus estimate of $0.74 million.

Armata Pharmaceuticals Price Performance

ARMP stock traded down $0.18 on Wednesday, reaching $8.82. 27,167 shares of the company traded hands, compared to its average volume of 55,359. Armata Pharmaceuticals has a one year low of $1.17 and a one year high of $16.34. The company has a market cap of $323.61 million, a P/E ratio of -1.83 and a beta of 1.31. The firm has a fifty day simple moving average of $10.55 and a 200-day simple moving average of $8.11.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their target price on Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $15.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC bought a new position in Armata Pharmaceuticals during the 4th quarter valued at approximately $164,000. OMERS ADMINISTRATION Corp bought a new position in Armata Pharmaceuticals during the 4th quarter valued at approximately $177,000. State Street Corp increased its position in Armata Pharmaceuticals by 26.1% during the 4th quarter. State Street Corp now owns 50,800 shares of the company’s stock valued at $319,000 after buying an additional 10,500 shares in the last quarter. Jane Street Group LLC bought a new position in Armata Pharmaceuticals during the 4th quarter valued at approximately $108,000. Finally, Renaissance Technologies LLC increased its position in Armata Pharmaceuticals by 65.9% during the 4th quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock valued at $430,000 after buying an additional 27,200 shares in the last quarter. Institutional investors own 3.57% of the company’s stock.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.